According to a statement by a market research institution, P&S Intelligence, the cell & gene therapy manufacturing services market generated a value of USD 5,151 million in 2022, and it will reach USD 20,164 million, propelling at an 18.60% compound annual growth rate, by 2030.
 |
| To learn more about this report: https://bit.ly/3BLTc1f |
The growth in the industry is credited to factors such as the numerous therapy development activities, the high cases of cancer as well as other target illnesses, and increased pharmaceutical research and development expenses.
In 2022, the cell therapy category accounted for a larger revenue share in the industry, of approximately 62%. This is primarily attributed to the extensive adoption of cell-based therapy for the clinical investigation of cardiovascular illnesses, because of rigorous pre-clinical studies of phenotypic efficacy, cell biology, immunology, and mechanism of action.
In 2022, the cell & gene therapy manufacturing services market was led by North America, with a revenue share of approximately 49%. This is because of the growing number of product launches, the rising emphasis on the treatment of rare diseases, the mounting prevalence of cancer cases, the existence of key industry players, and the increasing number of clinical trials in the region. Furthermore, advancements in technology in the region are boosting the requirement for gene therapies.
Europe accounted for a significant share of the industry. Approximately one-third of the overall population of 15 years and above are suffering from at least two chronic illnesses in the region, due to unhealthy diets, mounting alcohol consumption, and growing habits of smoking in the region.
Hence, with the high prevalence of cancer and other targeted illnesses, numerous therapy development activities, and increasing pharmaceutical research and development expenses, the global cell & gene therapy manufacturing services industry will grow significantly in the years to come.
